Skip to main content

Prostate Cancer Clinical Trials

Review the prostate cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 528

Nivolumab for the Treatment of DNA Repair-Mutated, Biochemically Recurrent Prostate Cancer, The NivoCure Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
High Intensity Focused Ultrasound for the Treatment of Radiorecurrent Localized Prostate Cancer
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
PSA Response-Based Radiation Therapy and Androgen Deprivation Therapy after Surgery for the Treatment of Relapsed Localized Prostate Cancer, RANGER Study
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Intermittent Compared to Continuous Relugolix and Androgen Receptor Pathway Inhibitor for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer, OPTIMAS Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide with Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Pembrolizumab with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
XL092 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, PRO-XL Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
An Investigational Scan (HP 13C MRI) for Assessing Response to Treatment with Abiraterone Acetate and Prednisone prior to Surgery in Patients with High-Risk Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Ivonescimab for the Treatment of Patients with Locally Advanced, Unresectable and/or Metastatic Cutaneous Squamous Cell Cancer and Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ESK981 for the Treatment of Patients with Select Advanced Solid Tumors
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
High Dose Rate Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Cell Therapy (STEAP1 CART) with Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Stereotactic Body Radiation Therapy and 177Lu-PSMA-617 for the Treatment of Locally Advanced Prostate Cancer, STARLiT Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Abemaciclib before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
REGN5678 before Surgery for Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas